http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107727752-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N30-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N30-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N30-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-64 |
| filingDate | 2016-08-12^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-11-08^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-11-08^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107727752-B |
| titleOfInvention | Analysis of the immunosuppressant everolimus |
| abstract | The invention relates to an analysis method for the immunosuppressant everolimus, which adopts high performance liquid chromatography; wherein, the stationary phase is reversed-phase silica gel; the mobile phase is composed of an aqueous phase and an organic phase, and the organic phase is acetonitrile and methanol of the mixture. The everolimus analysis method provided by the present invention has the advantages of practicality, reliability, accuracy and stability, simple operation, short analysis time, etc., and can achieve baseline separation between the main peak and the impurity peak, and between the impurity peak and the impurity peak, and is a kind of Effective means for quality assurance management. |
| priorityDate | 2016-08-12^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 40 of 40.